sapablursen   Click here for help

GtoPdb Ligand ID: 13914

Synonyms: Ionis-tmprss6-lrx | ISIS 702843 | ISIS-702843 | ISIS702843
Compound class: Nucleic acid
Comment: Sapablursen (ISIS 702843) is a N-acetyl galactosamine (GalNAc3) modified antisense oligonucleotide that is designed to reduce production of transmembrane protease serine 6 messenger (TMPRSS6) protein [1], as a mechanism to elevate expression of hepcidin and stabilise iron homeostasis in hematologic diseases.
Primary nucleotide sequence is provided without annotation of base and bond modifications, or glycan conjugation.
No information available.
Summary of Clinical Use Click here for help
Sapablursen (ISIS 702843) was advanced as a clinical candidate for the management of polycythemia vera (PV). It was was granted FDA Fast Track designation and orphan drug designation to treat PV in 2024. Ono Pharmaceutical progressed sapablursen to phase 3 for PV.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05143957 A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera Phase 2 Interventional Ionis Pharmaceuticals, Inc.
NCT04059406 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) Phase 2 Interventional Ionis Pharmaceuticals, Inc.
NCT07429266 INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV) Phase 3 Interventional Ono Pharmaceutical Co., Ltd.